It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with two PharmaLex experts about navigating complex R&D ...

Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 million, “primarily for debt paydown and general corporate purposes,” the company said ...

Walgreens is offloading more shares in drug distributor Cencora as the struggling pharmacy chain looks to generate cash. The latest sale netted about $300 million for Walgreens, and shrinks the ...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount ...

Cencora assumes no obligation to update any ... leadership in specialty in a high-growth pharmaceutical-centric segment building on our services for our customers and positioning us well in ...

Marks significant expansion of initiative to help health systems access critical, at-risk medications for patients Cencora, a global healthcare company, has significantly expanded the number and ...

Full Year Operating Income Growth Guidance: 11.5% to 13.5%. Cencora Inc (NYSE:COR) reported a strong start to fiscal year 2025 with a 13% increase in revenue and a 14% growth in adjusted EPS.

Full Year Adjusted EPS Guidance: Raised to $15.25 to $15.55. Full Year Revenue Growth Guidance: 8% to 10%. Full Year Operating Income Growth Guidance: 11.5% to 13.5%. Cencora Inc (NYSE:COR) reported a ...

Cencora assumes no obligation to update any forward-looking statements ... fits squarely into our strategy and growth by expanding our leadership in specialty in a high-growth pharmaceutical-centric ...